A global lighthouse project providing personalised treatment plans by merging Whole Genome Sequencing with drug screening, focusing initially on glioblastoma and pancreatic cancer.
Spearheading personalised treatment in Cancer Care: DEEP Diagnostics is a flagship project by Inspire2Live, championing the development of customised treatment and medication plans tailored to the unique needs of each patient. By integrating Whole Genome Sequencing with advanced drug screening techniques, our initiative crafts a comprehensive diagnostic toolbox. This approach allows us to identify specific DNA mutations and assess the effectiveness of treatments ex-vivo, directly on patient-derived tissue samples, enabling precise determination of the most effective therapies.
Focusing initially on addressing the critical needs of patients with glioblastoma and pancreatic cancer—two areas significantly lacking in attention and resources—we embarked on a journey to secure funding. Initially proposed as a single grant application, the complexity and distinct nature of each cancer led us to pursue separate proposals for more focused research efforts, both of which are currently in development.
The completion of these projects will mark a milestone in our quest to ascertain the feasibility of devising highly personalised treatment strategies. Inspire2Live is dedicated to transcending the limitations of conventional, one-size-fits-all approaches. Our mission is to shift the paradigm from a drug-centric to a patient-centric model, ensuring that treatments are not just available, but are optimally aligned with the individual patient’s needs and conditions, heralding a new era of Personalised Medicine.
